Ann: A World First for MCL in Autoimmune Disease Reasearch, page-38

The positives from todays announcement imo.

1) Committing 3 million dollars over three years suggests strong cash flow & sales from our only current source of income..Hemp.

2) A company willing to invest in it's future. I'm sure like all medical fields it will constantly evolve & to ensure success for share holders staying at the fore front of research & technology will be critical to long term stability.

3) The committments with Israel & Canntabb of million dollars suggests strong cash flow from Vitahemp, if this is in fact the case hopefully we can avoid any capital raisings in the near future. Unlike other mm companies it would appear we are going to have a strong cash flow from our hemp proping us up. Other mm companies may have to cr & dillute with no stream of income until their medical marijuana products can produce cash flow.

Looking forward to March/April & onwards.